238 related articles for article (PubMed ID: 30896451)
21. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
[TBL] [Abstract][Full Text] [Related]
22. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices.
Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B
Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903
[TBL] [Abstract][Full Text] [Related]
23. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.
Tsochatzis EA; Fatourou E; O'Beirne J; Meyer T; Burroughs AK
World J Gastroenterol; 2014 Mar; 20(12):3069-77. PubMed ID: 24695579
[TBL] [Abstract][Full Text] [Related]
24. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
25. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.
Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B
Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization and radioembolization.
Sangro B; Salem R
Semin Liver Dis; 2014 Nov; 34(4):435-43. PubMed ID: 25369305
[TBL] [Abstract][Full Text] [Related]
28. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
Sangro B
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
[TBL] [Abstract][Full Text] [Related]
29. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
30. DEB-TACE: a standard review.
Melchiorre F; Patella F; Pescatori L; Pesapane F; Fumarola E; Biondetti P; Brambillasca P; Monaco C; Ierardi AM; Franceschelli G; Carrafiello G
Future Oncol; 2018 Dec; 14(28):2969-2984. PubMed ID: 29987957
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
32. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
33. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
34. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
[TBL] [Abstract][Full Text] [Related]
35. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Su TH; Wu CH; Liu TH; Ho CM; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):230-241. PubMed ID: 36710607
[TBL] [Abstract][Full Text] [Related]
36. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
37. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
Facciorusso A
World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
[TBL] [Abstract][Full Text] [Related]
38. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
[TBL] [Abstract][Full Text] [Related]
39. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
40. The intermediate hepatocellular carcinoma stage: Should treatment be expanded?
Piscaglia F; Bolondi L
Dig Liver Dis; 2010 Jul; 42 Suppl 3():S258-63. PubMed ID: 20547312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
